Author

E Wijkmark

Institution: AstraZeneca (Sweden)

Observed institution: AstraZeneca (Sweden)

OpenAlex ID: A5159635505

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

2026 · E S Stroes, R S Rosenson, et al. · European Heart Journal

Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

2026 · E S Stroes, M Koren, et al. · European Heart Journal

Works count: 2

Citation count:

H-index:

I10-index: